Jim Cramer's Stop Trading: Shares of Acorda Therapeutics Deserve This Move Up

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called Ron Cohen, the CEO of Acorda Therapeutics (ACOR) , "one of the greatest CEOs" in the biotech industry.  

Must Read: 10 Stocks Carl Icahn Loves in 2014

The company's latest acquisition of Civitas for $525 million will help buildout Acorda's portfolio of treatments. 

Civitas is "apparently having great success" with its Parkinson's treatment, which is in Phase 3 trials, he said. 

Shares of Acorda Therapeutics are up 18% and are "correct in going higher," Cramer concluded, adding that the company is "remarkable."

Must Read: The Numbers Behind Facebook's Fight for Premium Video Content

 
-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

General Mills Buys Blue Buffalo for $8 Billion -- Who's Next?

General Mills Buys Blue Buffalo for $8 Billion -- Who's Next?

Time to Sell UPS Stock and Buy FedEx Instead?

Time to Sell UPS Stock and Buy FedEx Instead?

Video Game Sales Surge as Industry Momentum Remains Robust

Video Game Sales Surge as Industry Momentum Remains Robust

If Not Qualcomm, Who Should Broadcom Buy?

If Not Qualcomm, Who Should Broadcom Buy?

How Amazon's Stock Could Surge Another 17% to $1,750 a Share

How Amazon's Stock Could Surge Another 17% to $1,750 a Share